MRK
Merck & Co., Inc.
Key Financials
Net Income
$18.3B
↑ 6.6%
Total Assets
$136.9B
↑ 16.9%
Revenue
$65.0B
↑ 1.3%
Shareholders' Equity
$52.6B
↑ 13.6%
Cash & Equivalents
$14.6B
↑ 10.0%
EPS (Diluted)
$7.28
↑ 8.0%
Long-term Debt
$46.8B
↑ 35.7%
Operating Cash Flow
$16.5B
↓ 23.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| ARS | 4/8/2026 | View on SEC |
| DEFA14A | 4/8/2026 | View on SEC |
| DEF 14A | 4/8/2026 | View on SEC |
| SC TO-T | 4/7/2026 | View on SEC |
| 4 | 4/1/2026 | View on SEC |
| 4 | 4/1/2026 | View on SEC |
| 4 | 4/1/2026 | View on SEC |
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| 3 | 3/12/2026 | View on SEC |
| 10-K | 2/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MRK |
| Company Name | Merck & Co., Inc. |
| CIK | 310158 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NJ |
| Phone | 908-740-4000 |